Viking Therapeutics, Inc. (NASDAQ:VKTX) has been assigned a $5.00 price target by equities researchers at Maxim Group in a note issued to investors on Thursday. The firm presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s target price indicates a potential upside of 434.82% from the company’s previous close.

Several other analysts have also recently issued reports on VKTX. HC Wainwright reissued a “buy” rating and set a $7.00 price target (up previously from $5.00) on shares of Viking Therapeutics in a research report on Monday, July 17th. ValuEngine cut shares of Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th.

Viking Therapeutics (NASDAQ:VKTX) opened at 0.9349 on Thursday. Viking Therapeutics has a 52-week low of $0.88 and a 52-week high of $1.70. The firm’s 50-day moving average is $1.07 and its 200-day moving average is $1.28. The stock’s market cap is $22.37 million.

WARNING: “Viking Therapeutics, Inc. (NASDAQ:VKTX) Given a $5.00 Price Target by Maxim Group Analysts” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at

A hedge fund recently raised its stake in Viking Therapeutics stock. Renaissance Technologies LLC increased its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 62.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 265,800 shares of the biotechnology company’s stock after buying an additional 102,600 shares during the period. Renaissance Technologies LLC owned approximately 1.12% of Viking Therapeutics worth $388,000 at the end of the most recent reporting period. Institutional investors own 2.79% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with's FREE daily email newsletter.